SCHEMBL16601929

SCHEMBL16601929

Cc1ccc(SSc2ccc(C(C)C)cc2)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACHE P22303 3/20 0.43
BCHE P06276 1/20 0.43
FBP1 P09467 1/20 0.41
CHRNA7 P36544 1/20 0.39
TDP1 Q9NUW8 3/20 0.38
TYR P14679 2/20 0.38
LMNA P02545 2/20 0.38
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
MAPT P10636 2/20 0.37
NPSR1 Q6W5P4 2/20 0.37
ALDH1A1 P00352 1/20 0.37
HSP90AA1 P07900 1/20 0.37
MAPK1 P28482 1/20 0.37
AGTR1 P30556 1/20 0.37
ATM Q13315 1/20 0.37
BCL2 P10415 1/20 0.36
MCL1 Q07820 1/20 0.36
CNR2 P34972 1/20 0.36
SCN5A Q14524 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL944020 0.90 TYR (0.44) TYRLMNAMEN1KMT2AMAPT
SCHEMBL12552559 0.86 MCL1 (0.47) ACHEBCHECHRNA7TDP1TYR
P-Cymene SCHEMBL1697748 0.84 ACHE (0.53) ACHEBCHECHRNA7TDP1TYR
P-Cymene SCHEMBL1143 0.84 ACHE (0.53) ACHEBCHECHRNA7TDP1TYR
P-Cymene SCHEMBL31300110 0.82 ACHE (0.50) ACHEBCHECHRNA7TDP1TYR
P-Cymene SCHEMBL13735610 0.82 ACHE (0.50) ACHEBCHECHRNA7TDP1TYR
P-Cymene SCHEMBL31116717 0.82 ACHE (0.50) ACHEBCHECHRNA7TDP1TYR
P-Cymene SCHEMBL4860410 0.82 ACHE (0.50) ACHEBCHECHRNA7TDP1TYR
P-Cymene SCHEMBL31606590 0.82 ACHE (0.50) ACHEBCHECHRNA7TDP1TYR
P-Cymene SCHEMBL31578509 0.82 ACHE (0.50) ACHEBCHECHRNA7TDP1TYR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11697804-B2 Transcriptionally targeted and CpG-free plasmid for theranostic gene therapy THE JOHNS HOPKINS UNIVERSITY (US) 2023-07-11 US disclosed
US-8992991-B2 Multicomponent degradable cationic polymers THE JOHNS HOPKINS UNIVERSITY (US) 2015-03-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11697804-B2 Transcriptionally targeted and CpG-free plasmid for theranostic gene therapy POLRMT, HDGF, PCNP ACHE 4870/4885BCHE 4579/4885FBP1 2662/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.